Medical City Dallas has been singled out for its outstanding performance in the recent Sapien 3 transcatheter aortic valve replacement trial. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure for select patients with severe symptomatic aortic stenosis (narrowing of the aortic valve opening) who are not candidates for traditional open chest surgery.
The Sapien 3 study evaluated the safety and outcomes of minimally invasive transcatheter valve replacement in both high risk and intermediate risk surgical patients. Sixty-five hospitals from across the country participated in the study. Drs. Bruce Bowers and Todd Dewey served as the principal investigators for the trial at Medical City Dallas.
Overall, the results and outcomes demonstrated by Drs. Bowers and Dewey in the trial were the best of any site in the country. They had fewer complications and mortalities than any other site in the nation.
“We are honored to have participated in this landmark transcatheter aortic valve replacement trial. To have outperformed other nationally-recognized hospitals and health systems, is a credit to our incredible team of dedicated nurses and staff,” said Dr. Bruce S. Bowers, medical director of invasive and non-invasive cardiology, Medical City Dallas, and national medical director of interventional cardiology, Hospital Corporation of America. “Dr. Dewey and I are extraordinarily fortunate to be surrounded by a team of professionals that put us in the position to compete with the best cardiovascular programs in the country. This is an accomplishment that belongs to our incredible patients and to all of those that play a part in our valve program.”
“This is a landmark study utilizing the latest generation of technology, which Dallas Valve Institute was one of the first sites to introduce into the United States more than a decade ago,” said Dr. Todd M. Dewey, surgical director of structural heart disease, director of cardiac transplantation and circulatory support, Medical City Dallas, and national medical director of cardiovascular surgery, Hospital Corporation of America. “It has profound therapeutic opportunities with appropriate patients with valvular heart disease.”
Drs. Bowers and Dewey are currently leading three other minimally invasive valve trials at Medical City Dallas. To see what is new in minimally invasive valvular heart disease treatment, please visit dallasvalveinstitute.com or call the Dallas Valve Institute at Medical City at (972) 566-5050.
What is TAVR?
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure for select patients with severe symptomatic aortic stenosis (narrowing of the aortic valve opening) who are not candidates for traditional open chest surgery.
The surgical procedure repairs the valve without removing the old, damaged valve. Similar to a stent placed in an artery, the TAVR approach delivers a replacement valve through a catheter. Once the new valve is expanded, it takes over the job of regulating blood flow.
Usually valve replacement requires an open heart procedure with a “sternotomy” in which the chest is surgically separated (open) for the procedure. The TAVR procedure can be done through very small openings that leave all the chest bones in place.
At this time the procedure is reserved for those people for whom an open heart procedure is too risky. For this reason, most people who have this procedure are older and often have other medical conditions that make them a better candidate for this type of surgery. TAVR can be an effective option to improve quality of life in patients who otherwise have limited choices for repair of their aortic valve.
Source: American Heart Association